close
close

Leerink retires an Outperform rating for Tango Therapeutics-Aktie fest from Investing.com

Leerink retires an Outperform rating for Tango Therapeutics-Aktie fest from Investing.com

Leerink Partners has an Outperform rating and a stock price of US$19.00 for Tango Therapeutics Inc. (NASDAQ: TNGX) offered.

The Einschätzung der Firma follows the annual updates of biotech unternehmen on the PRMT5 inhibitors TNG908 and TNG462. Laut Leerink can perform this update on the Aktienkursentwicklung of the Unternehmens haben.

Tango Therapeutics plant, Daten von etwa 30-35 Patients für TNG462 vorzulegen, darunter etwa 20 met Expansionsdosen. For TNG908, data from 60-65 patients were used, of which 10 were concentrated with the 600 mg BID dose and 15-20 Glioblastoma (GBM) patients were separated. Learn an overview of the clinical and clinical data for PRMT5 inhibitors and learn the Wirksamkeits-Benchmarks for Tango Therapeutics.

The company looks at the major interests with kürzliche öffentlichten Daten von Amgens AMG193, das bei der ESMO 2024 an objective analysis (ORR) of 15% at the Gallengangkrebs (BTC) zeigte. Dieser Vergleich is relevant, da Tango Therapeutics ausreichende Stichprobengröße at BTC for a relative Analysis of vorweisen kann.

Leerink deutet an, that if the Wirksamkeit of TNG462 as Best-in-Class herausstellen konnte, trotz possible reviews for Investors bezüglich the Wirksamkeitsdaten at other Tumorarten. This is the latest update from Bristol Myers Squibb from 23.-25. October for BMS-986504 which changes the legal landscape.

The Tango Therapeutics stock has been trading for 52 weeks, influenced by the Amgens update at ESMO. Dennoch glaubt Leerink, de bevorstehende Datensatz TNG462 from Amgens Wirkstoff has a good chance, and verwess the most common preclinical properties of the drugs. Leerink bekräftigg und Positive Ausblick op des Potentials des TNG462 inner Markt Chances de MTAP-delete Krebsarten, die schätzungsweise 10-15% aller Krebserkrankungen ausmachen.

In others active Entwicklungen that Tango Therapeutics have carried out the Entwicklung sessions that have guided the Medikamentencandidates TNG348 through the study-related studies. During the liquidation of the internal systems during the year 2027, there were other therapeutic measures that the PRMT5 programs underwent, ermöglicht.

Analysts from Piper Sandler, HC Wainwright and Jefferies have rated the outside companies’ activities positively. Piper Sandler has expected more optimism for Tango Therapeutics’ proprietary PRMT5 inhibitors, TNG462 and TNG908, after the study concludes in late 2024. HC Wainwright came up with a Kaufrating with a stable price of 13.00 US-Dollar, while Jefferies selected a Kaufrating with a price soul of 19.00 US-Dollar.

InvestingPro Acknowledgment

Aktuelle InvestingPro-Daten are based on the context of Analysis by Leerink Partners at Tango Therapeutics (NASDAQ: TNGX). Trotz der probable Outperform-Bewertung und des Kursziels von 19,00 US-Dollar Steht TNGX für finnancial herausforderungen. The market capitalization of the US dollar was US$732.87 million, with a negative KGV of -6.25 for the last month to the second quarter of 2024, the active unprofitability was broader.

InvestingPro tips indicate that TNGX has made some money and it has not been profitable in those years. Focusing on the development of medicine in the clinical sector often involves investing in a successful commercial venture. The best performance of the active war with a return of -34.86% in the month of May, possibly influenced by the next update of the Amgen at the ESMO.

The positive thing about this brand name was that TNGX got more money as debt in the Bilanz country, a sure financing flexibility at the Weiterentwicklung of a clinical program that was possible. Darüber has the Umsatzwachstum of the Unternehmens of 26.16% in the letzten-zwölf Monaten on an anhaltende Geschäftsentwicklung trotz der Herausforderungen Hin.

For investors, the TNGX in Betracht sees, InvestingPro offers 10 other tips, which make even more money in the financial prosperity and market position of the Unternehmens that can be used. This sister information can be important for the clinical updates of the disease, the learning partners for the Aktienkursentwicklung-bedeutsam are of it, including wervoll sein.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.